J&J leads $7M round for German digital health co. Cara Care

fiercebiotech | June 18, 2019

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients, primarily in the U.S. Johnson & Johnson’s venture arm JJDC led the series A round alongside Asabys Partners, with Atlantic Labs also chipping in. Founded in 2016, Berlin-based Cara Care offers its app in German and English to patients with diseases such as irritable bowel syndrome, inflammatory bowel disease and gastrointestinal reflux disease. The company developed the app to bridge a gap in care for patients with these diseases and help them manage their medications and tweak their diets to improve their health. The company launched its app in 2016 and raised $2 million from angel investors the next year. It reckons about 400,000 people have used the app in Germany and the U.S. to manage their disease. Patients log their food, symptoms and medications in the Cara app, which sends them “dietary and mental health interventions” to help them control their symptoms between doctor’s visits.

Spotlight

Genetically modified?! Stem cell medical breakthrough!? More people living longer? More (healthy?) food from cloned animals and altered crops? Where is BIOTECH going? Is this a gamble we are willing to take? This four- part series investigates these questions and more as we head into the future.

Spotlight

Genetically modified?! Stem cell medical breakthrough!? More people living longer? More (healthy?) food from cloned animals and altered crops? Where is BIOTECH going? Is this a gamble we are willing to take? This four- part series investigates these questions and more as we head into the future.

Related News

Firmenich Opens New Biotechnology and Naturals Pilot Plant and Laboratory in Geneva

Firmenich | October 01, 2020

Firmenich, the world's largest privately-owned Perfume and Taste company, is proud to announce the opening of its new biotechnology and naturals pilot plant and laboratory in Geneva. Benefiting from the latest digital technology, the facility opens a new era for the development of ingredients and clean label solutions by providing faster speed-to-market and greater flexibility for customer collaboration. Integrated into the Group's flagship ingredients production site at La Plaine, Geneva, the facility operates to the highest safety and environmental standards, reducing waste and energy consumption. "With our new biotechnology pilot plant closely connected with the ingredients production site, Firmenich provides integrated biotech development all the way down to the finished product, without any gaps," said Genevieve Berger, Chief Research Officer, Firmenich. "Opening a new era in ingredients creation, our pilot plant and laboratory harnesses new technologies to improve clean label solutions, while the latest digital innovation maximizes efficiency." "Our new pilot plant provides greater flexibility to respond to customer needs in product development," said Sarah Reisinger, Senior Vice President Research Operations, Firmenich. "Capable of handling multiple projects simultaneously, it also enables small scale production of trial batches for formulation or testing and regulatory validation." Operational this month, the pilot plant at La Plaine is a cornerstone for new ingredients for both perfumery and flavors, enabling the development of the most efficient and high-quality production processes through biotechnology or natural extraction. Harnessing digital technology for increased automation, the pilot plant is able to move from single to continuous batch process, increasing efficiency, speed and reducing the use of raw materials.

Read More

INDUSTRIAL IMPACT

ADM Further Expands Microbial Science and Technology Innovation Capabilities with Investment in Precision Fermentation Leader Acies Bio

ADM | October 22, 2021

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re propelling growth opportunities by working with innovators who appreciate our unique combination of expertise, capacity and access to feedstocks. Now, by investing to become a minority owner in Acies Bio, we’re opening up the door to new collaboration with an innovative, complementary business to meet the growing demand for products developed via microbial fermentation.” Ian Pinner, ADM chief strategy and innovation officer. Founded in 2006, Acies Bio develops innovative, proprietary microbial and synthetic biology-based platforms and technologies and also offers contract R&D services in microbial strain engineering and fermentation for customers in key growth segments, including sustainable agriculture, functional foods and bio-based industrial chemicals. “Acies Bio’s core mission is to use the nearly unlimited power of microbial diversity to drive disruptive innovation and help create a more sustainable bio-based future,” said Enej Kuščer, Acies Bio's co-founder and director. “This strategic partnership with ADM will allow Acies Bio to expand and accelerate the development of our platform technologies, which aim to replace synthetic chemicals and the often carbon-intensive production currently used in food and agriculture with microbial, bio-based products.” “This investment from ADM will also allow Acies Bio to expand our infrastructure and increase the high-throughput capabilities of our SmartRoute platform, which will allow faster development of new technologies and products,” said Štefan Fujs, Acies Bio's co-founder and director. “This will speed-up the internal pipeline and also help us deliver more quality services to our partners and collaborators.” ADM’s investment in Acies Bio is being made through ADM Ventures, the company’s corporate venture capital arm. ADM Ventures invests in cutting-edge start-ups with disruptive technologies across three key areas: human nutrition, animal nutrition and sustainability. ADM Ventures also seeks startups that utilize ADM’s assets and feedstocks to produce sustainable materials, in addition to technologies that enhance the effectiveness or efficiency of ADM’s operations. About Acies Bio Acies Bio is a leading European microbial biotechnology company that develops new bioproducts and sustainable production processes for diverse industrial sectors, including pharma, food/feed, agricultural, and industrial biotechnology. With an emphasis on sustainability and using Acies Bio’s unique SmartRoute microbial platform, including synthetic biology and strain engineering, high-throughput screening, precision bioprocess and downstream development, the company has successfully developed and scaled numerous innovative products and precision fermentation technologies with industrial partners worldwide. About ADM At ADM, we unlock the power of nature to provide access to nutrition worldwide. With industry-advancing innovations, a complete portfolio of ingredients and solutions to meet any taste, and a commitment to sustainability, we give customers an edge in solving the nutritional challenges of today and tomorrow. We’re a global leader in human and animal nutrition and the world’s premier agricultural origination and processing company. Our breadth, depth, insights, facilities and logistical expertise give us unparalleled capabilities to meet needs for food, beverages, health and wellness, and more. From the seed of the idea to the outcome of the solution, we enrich the quality of life the world over.

Read More

CELL AND GENE THERAPY

2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach

2seventy bio, Inc | January 07, 2022

2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approach for hemophilia A patients with the goal of offering a sustained therapeutic effect. “This collaboration aims to develop the first direct in vivo application of our megaTAL technology. We are excited to explore this technology with Novo Nordisk, with the goal of developing a new potential therapeutic approach for patients with hemophilia A. Moreover, we view this work as further validation and a natural extension of our technology platform. Based on what we continue to learn, this technology may play a potential role in expanding our gene editing platform toward future in vivo and ex vivo applications that can enhance our oncology pipeline. We are also excited to announce a partnership between 2seventy bio and Genevant Sciences for the use of Genevant’s lipid nanoparticle platform in our collaboration with Novo Nordisk.” Philip Gregory, D. Phil., chief scientific officer, 2seventy bio The collaboration agreement with Novo Nordisk builds upon the original research collaboration signed between bluebird bio and Novo Nordisk in 2019, focused on identifying a development gene therapy candidate for people with hemophilia A. The collaboration utilizes 2seventy bio’s megaTAL technology that has the potential to provide a highly specific and efficient way to silence, edit, or insert genetic components. Hemophilia A is a genetic bleeding disorder resulting from defective Factor VIII. “We are excited to continue our partnership with 2seventy bio to jointly develop a next-generation in vivo genome editing treatment, with the ultimate ambition of offering people with hemophilia A lifetime free of factor replacement therapy,” said Karin Conde-Knape, senior vice president, Global Drug Discovery, Novo Nordisk. “This partnership reflects Novo Nordisk’s commitment to utilizing novel technology platforms to advance truly disease-modifying therapies for people with serious chronic diseases.” Under the terms of the agreement, Novo Nordisk will obtain the option to exclusively license 2seventy bio’s in vivo mRNA platform and gene editing technology for use in the treatment of patients with hemophilia A. 2seventy bio will receive an upfront payment of $5 million and is eligible for near-term milestone and option exercise payments of up to $35 million, in addition to development, regulatory, and commercial milestones, as well as a royalty on net sales. Novo Nordisk will be responsible for funding all research and development activities. Related to this collaboration, 2seventy bio has also entered into an agreement with Genevant Sciences for access to Genevant’s industry-leading LNP technology platform for use in 2seventy bio’s collaboration with Novo Nordisk for the treatment of patients with hemophilia A. 2seventy bio plans to use the Genevant LNP platform for efficient delivery of megaTAL mRNA to hepatocyte cells within the liver. “We are very pleased that 2seventy bio has entrusted Genevant and our LNP platform with delivery for its important gene editing program in hemophilia A,” said Pete Lutwyche, Ph.D., president and chief executive officer, Genevant Sciences Corporation. “Our scientists have been at the forefront of the LNP field for more than 20 years, and we are excited for our innovative technology to be used for this important application with great unmet need.” Under the terms of the agreement between 2seventy bio and Genevant, 2seventy bio obtained rights to license Genevant’s LNP technology for use with megaTAL mRNA products in the treatment of patients with hemophilia A. Genevant is eligible for upfront and near-term option exercise payments totaling $10 million, as well as development and commercialization milestones, and royalties in the mid-single digits on future product sales. About megaTALs MegaTALs are single-chain enzymes that combine the natural DNA recognition and cleavage processes of Homing Endonucleases with the modular DNA binding properties of transcription activator-like effectors. This protein fusion architecture allows the generation of highly specific and active nucleases in a compact format compatible with all current viral and non-viral cell delivery methods. About Novo Nordisk A/S Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. About Genevant Sciences Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle patent estate, and decades of experience and expertise in nucleic acid drug delivery and development. The Company’s scientists have pioneered LNP delivery of nucleic acids for over 20 years, and the Company’s LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved RNAi-LNP (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour — to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering new therapies and leveraging platform technologies that truly disrupt the cancer treatment landscape.

Read More